FR2797055B1 - Procede de criblage de molecules destinees au traitement de la maladie de huntington - Google Patents
Procede de criblage de molecules destinees au traitement de la maladie de huntingtonInfo
- Publication number
- FR2797055B1 FR2797055B1 FR9909855A FR9909855A FR2797055B1 FR 2797055 B1 FR2797055 B1 FR 2797055B1 FR 9909855 A FR9909855 A FR 9909855A FR 9909855 A FR9909855 A FR 9909855A FR 2797055 B1 FR2797055 B1 FR 2797055B1
- Authority
- FR
- France
- Prior art keywords
- huntington
- disease
- treatment
- screening molecules
- screening
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9909855A FR2797055B1 (fr) | 1999-07-29 | 1999-07-29 | Procede de criblage de molecules destinees au traitement de la maladie de huntington |
EP00953231A EP1200834A1 (fr) | 1999-07-29 | 2000-07-13 | Procede de criblage de molecules destinees au traitement de la maladie de huntington |
PCT/FR2000/002036 WO2001009613A1 (fr) | 1999-07-29 | 2000-07-13 | Procede de criblage de molecules destinees au traitement de la maladie de huntington |
CA002380519A CA2380519A1 (fr) | 1999-07-29 | 2000-07-13 | Procede de criblage de molecules destinees au traitment de la maladie de huntington |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9909855A FR2797055B1 (fr) | 1999-07-29 | 1999-07-29 | Procede de criblage de molecules destinees au traitement de la maladie de huntington |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2797055A1 FR2797055A1 (fr) | 2001-02-02 |
FR2797055B1 true FR2797055B1 (fr) | 2003-10-03 |
Family
ID=9548663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR9909855A Expired - Fee Related FR2797055B1 (fr) | 1999-07-29 | 1999-07-29 | Procede de criblage de molecules destinees au traitement de la maladie de huntington |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1200834A1 (fr) |
CA (1) | CA2380519A1 (fr) |
FR (1) | FR2797055B1 (fr) |
WO (1) | WO2001009613A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4819101A (en) * | 2000-04-13 | 2001-10-30 | University Of British Columbia, The | Modulating cell survival by modulating huntingtin function |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2116280A1 (fr) * | 1993-03-05 | 1994-09-06 | Marcy E. Macdonald | Gene de la huntingtine, son produit et leurs utilisations |
US6093549A (en) * | 1995-11-09 | 2000-07-25 | The Johns Hopkins University | Huntingtin-associated protein-related assays |
CA2238075A1 (fr) * | 1995-11-17 | 1997-05-29 | The University Of British Columbia | Proteine ayant une interaction avec le gene de la maladie de huntington, adnc codant cette proteine et anticorps contre celle-ci |
-
1999
- 1999-07-29 FR FR9909855A patent/FR2797055B1/fr not_active Expired - Fee Related
-
2000
- 2000-07-13 CA CA002380519A patent/CA2380519A1/fr not_active Abandoned
- 2000-07-13 WO PCT/FR2000/002036 patent/WO2001009613A1/fr not_active Application Discontinuation
- 2000-07-13 EP EP00953231A patent/EP1200834A1/fr not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
FR2797055A1 (fr) | 2001-02-02 |
EP1200834A1 (fr) | 2002-05-02 |
WO2001009613A1 (fr) | 2001-02-08 |
CA2380519A1 (fr) | 2001-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9600969A (pt) | Método de tratamento de doença inflamatória cardíaca | |
FR2798592B1 (fr) | Procede de traitement de troubles mataboliques, en particulier du diabete, ou d'une maladie ou d'une affection associee au diabete | |
CH1143977H1 (fr) | 2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite | |
MA23941A1 (fr) | Traitement des tissus | |
FR2794369B1 (fr) | Traitement de la maladie de peyronie | |
MA25223A1 (fr) | Procede pour la preparation de 4-carboxy-amino-2-substitue-1,2,3,4 tetrahydroquinoleine | |
KR970000230A (ko) | 염증성 장 질환을 치료하기 위한 캅파-아편제 작용물질 | |
EP1073368A4 (fr) | Procede base sur l'aspiration permettant d'evaluer les risques de pneumonie encourus par un patient post-operatoire | |
MA26608A1 (fr) | Procede de preparation d'une composition pharmaceutique destinee au traitement de l'insuffisance cardiaque. | |
FR2726994B1 (fr) | Cage agrafe pour fracture de l'extremite superieure de l'humerus | |
NO20001869D0 (no) | Fremgangsmõte for behandling av Alzheimerssykdom | |
FR2770216B1 (fr) | Procede d'obtention de la forme polymorphe epsilon de l'hexanitrohexaazaisowurtzitane | |
BR9711225A (pt) | Composi-{es de propentofilina transd-rmica para o tratamento do mal de alzheimer | |
FR2835255B1 (fr) | Test pour identifier des inhibiteurs de beta-secretases, procede de criblage de ces inhibiteurs, et nouveaux inhibiteurs de beta-secretases pour leur utilisation dans le traitement de la maladie d'alzheimer | |
ITTO940748A0 (it) | Condotto protesico particolarmente per il trattamento di patologie cardiovascolari. | |
NO20010953L (no) | En fremgangsmåte for behandling av stafylokokkal sykdom | |
BR9610316A (pt) | Composto processo para a produção e uso do mesmo processo para o tratamento de doença das vias aéreas e composição farmacêutica | |
FR2765591B1 (fr) | Procede de diagnostic de la maladie d'alzheimer | |
FR2775919B1 (fr) | Procede de traitement "mecano-chimique" d'un materiau | |
NO20012106L (no) | Middel for behandling av forstyrrelser i benmetabolismen | |
FR2778574B1 (fr) | Procede de mesure de l'effet d'un traitement sur un tissu | |
FR2797055B1 (fr) | Procede de criblage de molecules destinees au traitement de la maladie de huntington | |
FR2733227B1 (fr) | Procede pour la preparation de 1,1-difluoroethane | |
ATE230741T1 (de) | 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen | |
FR2719240B1 (fr) | Procédé de traitement des suspensions huileuses. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ST | Notification of lapse |